Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Lyell Immunopharma INC paid sponsored hires in similar roles1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Lyell Immunopharma INC paid sponsored hires in similar roles
- 1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
The preferred location for this role is hybrid based out of our South San Francisco, CA office.
POSITION SUMMARY:
The incumbent is responsible for formulating an integrated vision and strategy for communicating effectively with the investor community resulting in positive brand recognition and strong investor interest in Lyell. The Director or Senior Director, Investor Relations and Communications ensures that the Company’s scientific and clinical development strategy and progress are clearly communicated to investors, analysts, media, and the broad financial community. The person in this role must translate complex technical data into investment-driving narratives. Collaboration with executives and product teams on the delivery of external communications and corporate initiatives is essential to optimize the story of Lyell and its advances in science with investors, media, and industry organizations to broaden awareness and the brand of Lyell. Key duties include helping to develop and manage press releases, the corporate website, quarterly earnings filings, organizing conferences/roadshows, optimizing the corporate deck, determining corporate milestones to be communicated externally, and ensuring regulatory compliance.
KEY ROLE AND RESPONSIBILITIES:
• Collaborate with the C-suite and product teams to develop and execute a
communications strategy to share the importance of Lyell with investors via quarterly
filings, conference calls, investor conferences, and roadshows;
• Ensure that there is effective and consistent execution on the corporate communications
strategy to ensure optimal outreach to investors and analysts to keep Lyell’s strategy
and progress top of mind;
• Lead, develop and execute a comprehensive, strategic communications strategy and
tactical plan to achieve key investor relations objectives; evolve as needed;
• Partner with Finance and Legal to ensure investor-facing communications are robust,
timely and accurate, and provide compelling messaging and information.
• Develop written materials, such as key messages, FAQs and talking points to effectively
communicate the company’s positioning, decision, or program updates for conference
calls and other investor/analysts events.
• Train, advise, and develop spokespeople for media interviews, p
Apply on employer site ↗